10
Oct 25 (Reuters) – Johnson & Johnson: * JOHNSON & JOHNSON REPORTS 75% TUMOR RESPONSE RATE IN ADVANCED PROSTATE CANCER WITH JNJ-6143, A FIRST-IN-CLASS RIPTAC™ MOLECULE Further company coverage:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
